We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+14.38%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$347M
AUM Growth
-$92.7M
Cap. Flow
-$125M
Cap. Flow %
-36.15%
Top 10 Hldgs %
71.88%
Holding
54
New
11
Increased
5
Reduced
19
Closed
15
Avg Time Held
1.1 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
0.5 years

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.29M
2
A icon
Agilent Technologies
A
+$5.96M
3
ICLR icon
Icon
ICLR
+$5.89M
4
CNC icon
Centene
CNC
+$4.47M
5
RGEN icon
Repligen
RGEN
+$4.23M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$42.6M
2
NTRA icon
Natera
NTRA
+$12.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
4
DHR icon
Danaher
DHR
+$8.29M
5
MDT icon
Medtronic
MDT
+$8.06M

Sector Composition

Rank Sector Weight
1 Healthcare 98.84%
2 Consumer Staples 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DNTH icon
1
Dianthus Therapeutics
DNTH
$4.17B
$86.7M 25.01%
2,104,184
-1,100,000
-34% -$42.6M
2023 Q3
9 quarters
CGON icon
2
CG Oncology
CGON
$5.48B
$61.1M 17.64%
1,472,699
-128,200
-8% -$5.31M
2024 Q1
7 quarters
JBIO icon
3
Jade Biosciences
JBIO
$875M
$21.6M 6.23%
1,400,708
+273,522
+24% +$3.21M
2025 Q2
2 quarters
ORKA icon
4
Oruka Therapeutics
ORKA
$4.89B
$20M 5.77%
660,424
– –
2024 Q2
6 quarters
TEVA icon
5
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$13M 3.76%
417,300
-92,700
-18% -$2.28M
2025 Q1
3 quarters
BSX icon
6
Boston Scientific
BSX
$64B
$10.9M 3.15%
114,500
-49,800
-30% -$4.88M
2022 Q1
15 quarters
MDT icon
7
Medtronic
MDT
$122B
$10.3M 2.98%
107,600
-83,000
-44% -$8.06M
2025 Q3
1 quarter
CATX icon
8
Perspective Therapeutics
CATX
$267M
$8.83M 2.55%
3,210,733
+216,700
+7% +$618K
2024 Q2
6 quarters
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$31.3B
$8.35M 2.41%
+21,000
New +$9.29M
2025 Q4
0 quarters
RGEN icon
10
Repligen
RGEN
$11.7B
$8.24M 2.38%
50,300
+27,000
+116% +$4.23M
2025 Q2
2 quarters
CNTX icon
11
Context Therapeutics
CNTX
$22.1M
$8.09M 2.33%
5,504,855
-3,477,000
-39% -$4.06M
2024 Q2
6 quarters
MCK icon
12
McKesson
MCK
$116B
$7.81M 2.25%
9,520
+3,720
+64% +$3.04M
2025 Q2
2 quarters
ICLR icon
13
Icon
ICLR
$13.5B
$6.03M 1.74%
+33,100
New +$5.89M
2025 Q4
0 quarters
A icon
14
Agilent Technologies
A
$49.5B
$5.65M 1.63%
+41,500
New +$5.96M
2025 Q4
0 quarters
PFE icon
15
Pfizer
PFE
$168B
$5.07M 1.46%
203,600
-162,800
-44% -$4.11M
2025 Q3
1 quarter
CNC icon
16
Centene
CNC
$34.8B
$4.91M 1.42%
+119,400
New +$4.47M
2025 Q4
0 quarters
KVUE icon
17
Kenvue
KVUE
$35.9B
$4.02M 1.16%
232,800
-32,400
-12% -$530K
2025 Q3
1 quarter
DHR icon
18
Danaher
DHR
$163B
$3.89M 1.12%
17,000
-37,700
-69% -$8.29M
2023 Q3
9 quarters
TMO icon
19
Thermo Fisher Scientific
TMO
$258B
$3.88M 1.12%
6,700
-12,200
-65% -$6.9M
2023 Q4
8 quarters
NVO icon
20
Novo Nordisk
NVO
$173B
$3.42M 0.99%
+67,300
New +$3.44M
2025 Q4
0 quarters
PHAT icon
21
Phathom Pharmaceuticals
PHAT
$607M
$3.42M 0.99%
206,076
-99,924
-33% -$1.43M
2021 Q4
16 quarters
EHC icon
22
Encompass Health
EHC
$12.6B
$3.35M 0.97%
31,600
-10,300
-25% -$1.19M
2025 Q2
2 quarters
CI icon
23
Cigna
CI
$79B
$3.19M 0.92%
11,600
-5,000
-30% -$1.4M
2025 Q3
1 quarter
COR icon
24
Cencora
COR
$65.2B
$3.17M 0.92%
9,400
-9,600
-51% -$3.27M
2025 Q1
3 quarters
INSM icon
25
Insmed
INSM
$21.7B
$3.08M 0.89%
17,700
+6,100
+53% +$1.11M
2024 Q2
6 quarters
1
2 3

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q4 2025 Portfolio in Review

As of Q4 2025, Avidity Partners Management held 54 positions worth $347M, down 21% from $439M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Avidity Partners Management withdrew a net $125M in Q4 2025, closing 15 positions and reducing 19 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $11.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Consumer Staples.

Against the trend, Avidity Partners Management opened a new position in Alnylam Pharmaceuticals worth $8.35M.

  • Avidity Partners Management's largest Q4 2025 buy was Alnylam Pharmaceuticals: 21,000 shares worth $8.35M.
  • Avidity Partners Management added most to Repligen in Q4 2025, an estimated $4.23M increase.
  • Avidity Partners Management's biggest Q4 2025 reduction was Dianthus Therapeutics, cutting an estimated $42.6M.
  • Avidity Partners Management fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $11.6M.
  • Avidity Partners Management's ten largest holdings make up 72% of its $347M portfolio in Q4 2025.
  • Avidity Partners Management opened 11 new positions and closed 15 in Q4 2025.
  • Avidity Partners Management's portfolio value fell 21% quarter-over-quarter to $347M.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.